Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 4 1Phase 2 1

Status

Completed 4

Sponsor Class

OTHER 29NETWORK 17NIH 7INDUSTRY 4FED 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Tumor-Agnostic 1

Conditions

Prostatic Neoplasms 3Adenocarcinoma 1

Interventions

pembrolizumab 1029Carboplatin 966Paclitaxel 941Gemcitabine 798Cisplatin 754Docetaxel 697Bevacizumab 638Nivolumab 519Pemetrexed 507Capecitabine 475Cyclophosphamide 468Fluorouracil 424Dexamethasone 409Rituximab 391Oxaliplatin 351Injections 344Trastuzumab 313atezolizumab 311Cetuximab 291Leucovorin 288Irinotecan 269130-nm albumin-bound paclitaxel 255Prednisone 250Ipilimumab 244Doxorubicin 241Lenalidomide 231Fulvestrant 226fludarabine 215durvalumab 211Erlotinib Hydrochloride 196

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
INDUSTRY × Flutamide × Clear all
NCT02918968 2024-12-09

Study on Enzalutamide and Flutamide in Patients With Castration Resistant Prostate Cancer

Astellas Pharma Inc

Phase 4 Completed
206 enrolled 16 charts
Genitourinary

Prostatic Neoplasms

NCT01011751 2015-07-30

Treatment of Hot Flushes Caused by Leuprorelin 11.25 mg in Prostate Adenocarcinoma

Takeda

Phase 3 Completed
311 enrolled
Tumor-Agnostic

Adenocarcinoma

NCT00817739 2015-07-29

Intermittent Hormonal Therapy With Leuprorelin and Flutamide in the Treatment of Stage D2 or TxNxM1b,c

Takeda

Phase 2 Completed
341 enrolled
Genitourinary

Prostatic Neoplasms

NCT01122121 2015-07-29

Leuprorelin Associated With Radiotherapy Versus Leuprorelin Alone in T3 - T4 or pT3 (on Biopsy) N0, M0 Prostate Cancer

Takeda

Phase 3 Completed
273 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡